NRx Pharmaceuticals, Inc. NRXP NASDAQ

NRx Pharmaceuticals, Inc. (NRXP) has a negative trailing P/E of -2.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -40.54%, forward earnings yield 44.64%. PEG 0.02 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

• VALUE (10/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -2.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -40.54%); analyst consensus target implies downside from the current price ($2.00, 20.6%).
• Forward P/E 2.2 — analysts expect a return to profitability with estimated EPS of $1.12 for FY2026.
• PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
• Trailing Earnings Yield -40.54% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 44.64% as earnings recover.
• Analyst consensus target $2.00 (-20.6% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 27/100 with 2/7 criteria passed.